Current Headlines

91. BioLineRx Receives Regulatory Approval To Commence Phase II Clinical Trial For BL-8040, For Treatment Of Leukemia
    4/10/2013

    BioLineRx, a biopharmaceutical development company, announced recently that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia (AML).

92. NIH-Funded Researchers Create Next-Generation Alzheimer’s Disease Model
    4/9/2013

    A new genetically engineered lab rat that has the full array of brain changes associated with Alzheimer’s disease supports the idea that increases in a molecule called beta-amyloid in the brain causes the disease, according to a study, published in the Journal of Neuroscience.

93. Green Valley Drugs Announces Voluntary Nationwide Recall Of All Lots Of All Sterile Products Compounded, Repackaged, And Distributed By Green Valley Drugs Due To Quality Control Concerns
    4/5/2013

    Green Valley Drugs is voluntarily recalling All Lots of All Sterile products compounded, repackaged, and distributed by the pharmacy due to lack of sterility assurance and concerns associated with the quality control processes.

94. InVivo Therapeutics Receives Approval From FDA For First Human Trial Using Biomaterials For Traumatic Spinal Cord Injury
    4/5/2013

    InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, recently announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) to begin human studies to test its biopolymer scaffold product, a technology developed to treat patients with acute, traumatic SCI. 

95. Emergent BioSolutions To Expand Front Line CLL Clinical Trial Of TRU-016 And Rituximab Based On Strong Patient Enrollment And Encouraging Early Clinical Data
    4/5/2013

    Emergent BioSolutions Inc. recently announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol 16009) evaluating the safety and efficacy of TRU-016 in combination with rituximab in previously untreated patients with chronic lymphocytic leukemia (CLL). 

96. Predictive Biosciences To Present At AACR Annual Meeting And Oak Ridge Conference
    4/5/2013

    Predictive Biosciences, an innovative developer of molecular diagnostic tests, recently announced the company will present data at two key scientific conferences this month on the latest in bladder cancer advancements using next-generation sequencing for multiple biomarker detection. 

97. Aduro Announces Upcoming Presentations On Oncology Programs At American Association Of Cancer Research Meeting
    4/5/2013

    Aduro BioTech, Inc. announces one oral and two poster presentations at the upcoming American Association of Cancer Research (AACR) Annual Meeting April 6th-10th in Washington, D.C. that highlight the breadth and progress of Aduro’s Listeria monocytogenes-based and cyclic dinucleotide (CDN)-based immunotherapy programs. 

98. PYRAMID Laboratories Inc., Completes Successful FDA Audit
    4/4/2013

    PYRAMID Laboratories, Inc., a premier service provider of cGMP contract development and sterile manufacturing services for the pharmaceutical, biotech, and medical device industries is pleased to announce it successfully completed a four day cGMP audit of its manufacturing and laboratory facilities.

99. Azbil BioVigilant (ABV) Announces Partnership With University Of Tennessee (UT) Pharmacy College
    4/4/2013

    Azbil BioVigilant, Inc.,inventors of Instantaneous Microbial Detection, announced recently that the University of Tennessee (UT) Pharmaceutical Sciences Department will utilize Azbil BioVigilant’s IMD-A 300-series of rapid microbial monitoring systems in their state-of-the-art aseptic filling facility.

100. Antibody Evolution Could Guide HIV Vaccine Development
     4/4/2013

     Observing the evolution of a particular type of antibody in an infected HIV-1 patient, a study spearheaded by Duke University, including analysis from Los Alamos National Laboratory, has provided insights that will enable vaccination strategies that mimic the actual antibody development within the body.